Hiperlipidemia familiar combinadadocumento de consenso
- Mata López, Pedro
- Alonso, Rodrigo
- Ruiz García, Antonio
- Díaz Díaz, José Luis
- González Pérez de Villar, Noemí
- Gijón Conde, Teresa
- Martínez Faedo, Ceferino
- Morón Merchante, Ignacio
- Arranz Martínez, Ezequiel
- Aguado Matilla, Rocío
- Argüeso Armesto, Rosa
- Pérez de Isla, Leopoldo
ISSN: 1138-3593
Ano de publicación: 2014
Número: 7
Páxinas: 374-380
Tipo: Artigo
Outras publicacións en: Semergen: revista española de medicina de familia
Obxectivos de Desenvolvemento Sustentable
Resumo
Familial combined hyperlipidemia (FCH) is a frequent disorder associated with premature coronary artery disease. It is transmitted in an autosomal dominant manner, although there is not a unique gene involved. The diagnosis is performed using clinical criteria, and variability in lipid phenotype and family history of hyperlipidemia are necessaries. Frequently, the disorder is associated with type 2 diabetes mellitus, arterial hypertension and central obesity. Patients with FCH are considered as high cardiovascular risk and the lipid target is an LDL-cholesterol < 100 mg/dL, and < 70 mg/dL if cardiovascular disease or type 2 diabetes are present. Patients with FCH require lipid lowering treatment using potent statins and sometimes, combined lipid-lowering treatment. Identification and management of other cardiovascular risk factors as type 2 diabetes and hypertension are fundamental to reduce cardiovascular disease burden. This document gives recommendations for the diagnosis and global treatment of patients with FCH directed to specialists and general practitioners.